Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home

Project cooperationUpdated on 9 April 2026

ASPER2

Filip Rázga

CEO at Selecta Biotech SE

Bratislava, Slovakia

About

ASPER2 is a therapeutic oligonucleotide based on the ESiNAR-X platform, intended for patients with gradually progressive chronic kidney disease accompanied by renal fibrosis.

Status: Finished pre-clinical validation

We are seeking investments and partnerships to support the execution of clinical trials.

Similar opportunities

  • Project cooperation

    ASP210

    Filip Rázga

    CEO at Selecta Biotech SE

    Bratislava, Slovakia

  • Project cooperation

    ASC1R

    Filip Rázga

    CEO at Selecta Biotech SE

    Bratislava, Slovakia

  • Project cooperation

    Next-Gen Diagnostics for CKM & CKD Management and Therapy Development

    • Research
    • Execution
    • Technical
    • Healthcare
    • EU projects
    • Biotech, Pharma and Cosmetics
    • Partner looking for consortium
    • Food, Beverages and Agriculture

    Ming Zou

    Chief Medical Officer at Quant Biomarkers

    Basel, Switzerland